Observational studyAnnals of medicine2024
Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients.
Observational study in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- New advances in the treatment of chronic rhinosinusitis with nasal polyps from pathophysiology to biologic targeted therapy.Frontiers in allergy · 2026Pooled it
- Does Patient-Reported Olfactory Improvement Correlate with Quality of Life and Polyp Size Reduction in Patients with CRSwNP Treated with Dupilumab?Medicines (Basel, Switzerland) · 2026Article
- The Use of Biological Therapies in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Current State of Knowledge.Journal of clinical medicine · 2026Review
- Unsupervised Machine-Learning-Based Endotype Discovery Using Iterative Resampling in Dupilumab-Treated Patients.International journal of molecular sciences · 2026Article
- Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications-An EAACI Task Force Report.Allergy · 2026Article
- Modifying the course of asthma: mechanisms and strategies for clinical remission.Current opinion in allergy and clinical immunology · 2026Review
- Advance in biologics for chronic rhinosinusitis with nasal polyps.Frontiers in allergy · 2026Review
- Real-World Response to Dupilumab as Add-on Therapy in Adults and Adolescents with Type 2 Severe Asthma: A Spanish Cohort Study.Journal of asthma and allergy · 2026Article
- Comorbidities as a Personalized Target in Patients with Severe Asthma Treated with Dupilumab.Journal of personalized medicine · 2025Article
- The management of type 2 inflammatory respiratory diseases: a Chinese expert consensus [2024].Journal of thoracic disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDupilumab, an anti-IL-4 receptor monoclonal antibody (mAb), was recently approved for the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP). The main objective of this study was to assess whether previous exposure to biological treatment affected the clinical outcomes in CRSwNP and asthma patients, treated with dupilumab over time. A collateral secondary objective was to analyse the effects over time of dupilumab in patients with and without aeroallergen sensitization.
methodsSingle-centre retrospective observational study on severe CRSwNP patients treated with dupilumab. Nasal polyp score (NPS), visual analogue scale (VAS) symptom score, sinonasal outcome test (SNOT-22), aeroallergen sensitization, total serum IgE levels, and blood eosinophil counts were assessed at baseline and after 4, 6 and 12 months.
results42 patients were included, 40 (95.2%) had asthma. Twenty-one (50%) patients received dupilumab without prior biological treatment (Group A: naive) and 50% switched to dupilumab from previous biological treatment (Group B: pre-treated). NPS, VAS symptoms, SNOT-22 improved significantly after 12 months treatment in both groups of patients (
conclusionsDupilumab improves symptom severity, polyp size, and health-related quality of life, regardless of the presence or absence of comorbid aeroallergen sensitization and previous administration of biologic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.